Paul-Ehrlich-Institut

Hinweis zur Verwendung von Cookies

Zur Bereitstellung und Optimierung unseres Webauftritts möchten wir gerne statistische Informationen vollständig anonymisiert erfassen und analysieren. Dürfen wir hierzu vorübergehend einen Statistik-Cookie setzen?

Sie können Ihre Einwilligung jederzeit in unserer Datenschutzerklärung widerrufen.

OK

Publikationen apl. Prof. Dr. Christian Buchholz

Autorinnen und Autoren des Paul-Ehrlich-Instituts sind durch Fettdruck kenntlich gemacht. Wenn Online-Abstracts oder Volltexte zu den Publikationen verfügbar sind, so sind diese verlinkt.

Jamali A, Ho N, Braun A, Adabi E, Thalheimer FB, Buchholz CJ (2024): Early induction of cytokine release syndrome by rapidly generated CAR T cells in preclinical models.
EMBO Mol Med Mar 21 [Epub ahead of print].
Text

Braun AH, Frank AM, Ho N, Buchholz CJ (2023): Dasatinib is a potent enhancer for CAR T cell generation by CD3-targeted lentiviral vectors.
Mol Ther Methods Clin Dev 28: 90-98.
Text

Schambach A, Buchholz CJ, Torres-Ruiz R, Cichutek K, Morgan M, Trapani I, Büning H (2023): A new age of precision gene therapy.
Lancet Nov 22 [Epub ahead of print].
Online-Abstract

Theuerkauf SA, Herrera-Carrillo E, John F, Zinser LJ, Molina MA, Riechert V, Thalheimer FB, Börner K, Grimm D, Chlanda P, Berkhout, Buchholz CJ (2023): AAV vectors displaying bispecific DARPins enable dual-control targeted gene delivery.
Biomaterials 303: 122399.
Text

Bold CS, Baltissen D, Ludewig S, Back MK, Just J, Kilian L, Erdinger S, Banicevic M, Rehra L, Almouhanna F, Nigri M, Wolfer DP, Spilger R, Rohr K, Kann O, Buchholz CJ, von Engelhardt J, Korte M, Müller UC (2022): APPsα Rescues Tau-Induced Synaptic Pathology.
J Neurosci 42: 5782-5802.
Online-Abstract

Denk D, Petrocelli V, Conche C, Drachsler M, Ziegler PK, Braun A, Kress A, Nicolas AM, Mohs K, Becker C, Neurath MF, Farin HF, Buchholz CJ, Andreux PA, Rinsch C, Greten FR (2022): Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy.
Immunity 55: 2059-2073.
Text

Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I (2022): Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?.
J Immunother Cancer 10: e003487.
Text

Ho N, Agarwal S, Milani M, Cantore A, Buchholz CJ, Thalheimer FB (2022): In vivo generation of CAR T cells in the presence of human myeloid cells.
Mol Ther Methods Clin Dev 26: 144-156.
Text

Michels A, Ho N, Buchholz CJ (2022): Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.
Mol Ther 30: 2401-2415.
Text

Strecker MI, Wlotzka K, Strassheimer F, Roller B, Ludmirski G, König S, Röder J, Opitz C, Alekseeva T, Reul J, Sevenich L, Tonn T, Wels WS, Steinbach JP, Buchholz CJ, Burger MC (2022): AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
Oncoimmunology 11: e2127508.
Text

Charitidis FT, Adabi E, Thalheimer FB, Clarke C, Buchholz CJ (2021): Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics.
Mol Ther Methods Clin Dev 23: 359-369.
Online-Abstract

Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C, EICCI Faculty Group (2021): Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15 th-16 th February 2019, Doha, Qatar.
Front Immunol 11: 589381.
Text

Michels A, Frank AM, Günther DM, Mataei M, Börner K, Grimm D, Hartmann J, Buchholz CJ (2021): Lentiviral and adeno-associated vectors efficiently transduce mouse T lymphocytes when targeted to murine CD8.
Mol Ther Methods Clin Dev 23: 334-347.
Online-Abstract

Theuerkauf SA, Michels A, Riechert V, Maier TJ, Flory E, Cichutek K, Buchholz CJ (2021): Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without.
iScience 24: 102170.
Online-Abstract

Veinalde R, Pidelaserra-Martí G, Moulin C, Jeworoski LM, Küther L, Buchholz CJ, Jäger D, Ungerechts G, Engeland CE (2021): Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory.
Mol Ther Oncolytics 24: 43-58.
Text

Weidner T, Agarwal S, Perian S, Fusil F, Braun G, Hartmann J, Verhoeyen E, Buchholz CJ (2021): Genetic in vivo engineering of human T lymphocytes in mouse models.
Nat Protoc 16: 3210-3240.
Text

Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ (2020): In vivo generation of CAR T cells selectively in human CD4+ lymphocytes.
Mol Ther 28: 1783-1794.
Text

Frank AM, Braun AH, Scheib L, Agarwal S, Schneider IC, Fusil F, Perian S, Sahin U, Thalheimer FB, Verhoeyen E, Buchholz CJ (2020): Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.
Blood Adv 4: 5702-5715.
Text

Frank AM, Weidner T, Brynza J, Uckert W, Buchholz CJ, Hartmann J (2020): CD8-Specific Designed Ankyrin Repeat Proteins Improve Selective Gene Delivery Into Human and Primate T Lymphocytes.
Hum Gene Ther 31: 679-691.
Online-Abstract

Michels A, Hartmann J, Buchholz CJ (2020): Chimäre Antigenrezeptoren (CARs) in der Onkologie: eine Übersicht zu klinischer Anwendung und neuen Entwicklungen.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63: 1331-1340.
Online-Abstract

Patasic L, Seifried J, Bezler V, Kaljanac M, Schneider IC, Schmitz H, Tondera C, Hartmann J, Hombach A, Buchholz CJ, Abken H, König R, Cichutek K (2020): Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4 + T cells to reduce the latent HIV + cell reservoir.
Med Microbiol Immunol 209: 681-691.
Online-Abstract

Agarwal S, Weidner T, Thalheimer FB, Buchholz CJ (2019): In vivo generated human CAR T cells eradicate tumor cells.
Oncoimmunology 8: e1671761.
Online-Abstract

Frank AM, Buchholz CJ (2019): Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.
Mol Ther Methods Clin Dev 12: 19-31.
Text

Hartmann J, Thalheimer FB, Höpfner F, Kerzel T, Khodosevich K, García-González D, Monyer H, Diester I, Büning H, Carette JE, Fries P, Buchholz CJ (2019): GluA4-Targeted AAV Vectors Deliver Genes Selectively to Interneurons while Relying on the AAV Receptor for Entry.
Mol Ther Methods Clin Dev 14: 252-260.
Text

Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J (2019): Highly Efficient and Selective CAR-Gene Transfer Using CD4- and CD8-Targeted Lentiviral Vectors.
Mol Ther Methods Clin Dev 13: 371-379.
Text

Reul J, Frisch J, Engeland CE, Thalheimer FB, Hartmann J, Ungerechts G, Buchholz CJ (2019): Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors.
Front Oncol 9: 52.
Text

Reul J, Muik A, Buchholz CJ (2019): Ligand Coupling to the AAV Capsid for Cell-Specific Gene Transfer.
Methods Mol Biol 1950: 35-50.
Online-Abstract

Hanauer JDS, Rengstl B, Kleinlützum D, Reul J, Pfeiffer A, Friedel T, Schneider IC, Newrzela S, Hansmann ML, Buchholz CJ, Muik A (2018): CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.
Oncotarget 9: 12971-12981.
Online-Abstract

Hartmann J, Münch RC, Freiling RT, Schneider IC, Dreier B, Samukange W, Koch J, Seeger MA, Plückthun A, Buchholz CJ (2018): A Library-Based Screening Strategy for the Identification of DARPins as Ligands for Receptor-Targeted AAV and Lentiviral Vectors.
Mol Ther Methods Clin Dev 10: 128-143.
Text

Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, Costa C, Wels WS, Modlich U, Stripecke R, Verhoeyen E, Buchholz CJ (2018): In vivo generation of human CD19-CAR T cells results in B cell depletion and signs of cytokine release syndrome.
EMBO Mol Med 10: e9158.
Text

Richter MC, Ludewig S, Winschel A, Abel T, Bold C, Salzburger LR, Klein S, Han K, Weyer SW, Fritz AK, Laube B, Wolfer DP, Buchholz CJ, Korte M, Müller UC (2018): Distinct in vivo roles of secreted APP ectodomain variants APPsα and APPsβ in regulation of spine density, synaptic plasticity, and cognition.
EMBO J 37: e98335.
Online-Abstract

Schneider IC, Hartmann J, Braun G, Stitz J, Klamp T, Bihi M, Sahin U, Buchholz CJ (2018): Displaying Tetra-Membrane Spanning Claudins on Enveloped Virus-Like Particles for Cancer Immunotherapy.
Biotechnol J 13: e1700345.
Online-Abstract

Buchholz CJ, Hartmann J, Schüssler-Lenz M, Keller-Stanislawski B (2017): Neue Entwicklung in der Onkologie: CAR-T-Zelltherapie.
Bulletin zur Arzneimittelsicherheit 8: 31-35.
Text

Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ (2017): Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts.
EMBO Mol Med 9: 1183-1197.
Text

Kleinlützum D, Hanauer JDS, Muik A, Hanschmann KM, Kays SK, Ayala-Breton C, Peng KW, Mühlebach MD, Abel T, Buchholz CJ (2017): Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.
Front Oncol 7: Article 127.
Text

Manavski Y, Abel T, Hu J, Kleinlützum D, Buchholz CJ, Belz C, Augustin HG, Boon RA, Dimmeler S (2017): Endothelial transcription factor KLF2 negatively regulates liver regeneration via induction of activin A.
Proc Natl Acad Sci U S A 114: 3993-3998.
Online-Abstract

Muik A, Reul J, Friedel T, Muth A, Hartmann KP, Schneider IC, Münch RC, Buchholz CJ (2017): Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer.
Biomaterials 144: 84-94.
Online-Abstract

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM (2017): Virotherapy Research in Germany: From Engineering to Translation.
Hum Gene Ther 28: 800-819.
Online-Abstract

Wagner J, Pfannenstiel V, Waldmann A, Bergs JWJ, Brill B, Huenecke S, Klingebiel T, Rödel F, Buchholz CJ, Wels WS, Bader P, Ullrich E (2017): A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma.
Front Immunol 8: 676.
Text

Wang X, Herzog RW, Byrne BJ, Kumar SRP, Zhou Q, Buchholz CJ, Biswas M (2017): Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells.
Mol Ther Methods Clin Dev 5: 76-82.
Online-Abstract

Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Plückthun A, Maisner A, Buchholz CJ (2016): Receptor-targeted Nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane proximal cell attachment.
PLOS Pathog 12: e1005641.
Text

Fol R, Braudeau J, Ludewig S, Abel T, Weyer SW, Roederer JP, Brod F, Audrain M, Bemelmans AP, Buchholz CJ, Korte M, Cartier N, Müller UC (2016): Viral gene transfer of APPsα rescues synaptic failure in an Alzheimer's disease mouse model.
Acta Neuropathol 131: 247-266.
Online-Abstract

Friedel T, Jung-Klawitter S, Sebe A, Schenk F, Modlich U, Ivics Z, Schumann GG, Buchholz CJ, Schneider IC (2016): CD30 receptor-targeted lentiviral vectors for human induced pluripotent stem cell-specific gene modification.
Stem Cells Dev 25: 729-739.
Online-Abstract

Hanauer JR, Gottschlich L, Riehl D, Rusch T, Koch V, Friedrich K, Hutzler S, Prüfer S, Friedel T, Hanschmann KM, Münch RC, Jost C, Plückthun A, Cichutek K, Buchholz CJ, Mühlebach MD (2016): Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors.
Mol Ther Oncolytics 3: 16003.
Text

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS (2016): Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Int J Cancer 139: 1799-1809.
Online-Abstract

Brendel C, Goebel B, Daniela A, Brugman M, Kneissl S, Schwäble J, Kaufmann KB, Müller-Kuller U, Kunkel H, Chen-Wichmann L, Abel T, Serve H, Bystrykh L, Buchholz CJ, Grez M (2015): CD133-targeted Gene Transfer Into Long-term Repopulating Hematopoietic Stem Cells.
Mol Ther 23: 63-70.
Online-Abstract

Buchholz CJ, Friedel T, Büning H (2015): Surface-Engineered Viral Vectors for Selective and Cell Type-Specific Gene Delivery.
Trends Biotechnol 33: 777-790.
Online-Abstract

Chamoun-Emanuelli AM, Wright G, Smith R 3rd, Münch RC, Buchholz CJ, Chen Z (2015): In vitro incorporation of a cell-binding protein to a lentiviral vector using an engineered split intein enables targeted delivery of genetic cargo.
Biotechnol Bioeng 112: 2611-2617.
Online-Abstract

Friedel T, Hanisch LJ, Muth A, Honegger A, Abken H, Plückthun A, Buchholz CJ, Schneider IC (2015): Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv.
Protein Eng Des Sel 28: 93-106.
Online-Abstract

Kays SK, Kaufmann KB, Abel T, Brendel C, Bonig H, Grez M, Buchholz CJ, Kneissl S (2015): CD105 Is a Surface Marker for Receptor-Targeted Gene Transfer into Human Long-Term Repopulating Hematopoietic Stem Cells.
Stem Cells Dev 24: 714-723.
Online-Abstract

Münch RC, Muth A, Muik A, Friedel T, Schmatz J, Dreier B, Trkola A, Plückthun A, Büning H, Buchholz CJ (2015): Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.
Nat Commun 6: 6246.
Online-Abstract

Uhlig KM, Schülke S, Scheuplein VA, Malczyk AH, Reusch J, Kugelmann S, Muth A, Koch V, Hutzler S, Bodmer BS, Schambach A, Buchholz CJ, Waibler Z, Scheurer S, Mühlebach MD (2015): Lentiviral protein transfer vectors are an efficient vaccine-platform inducing strong antigen-specific cytotoxic T cell response.
J Virol 89: 9044-9060.
Online-Abstract

Zhou Q, Uhlig KM, Muth A, Kimpel J, Levy C, Münch RC, Seifried J, Pfeiffer A, Trkola A, Coulibaly C, von Laer D, Wels WS, Hartwig UF, Verhoeyen E, Buchholz CJ (2015): Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors.
J Immunol 195: 2493-2501.
Online-Abstract

Bayin NS, Modrek AS, Dietrich A, Lebowitz J, Abel T, Song HR, Schober M, Zagzag D, Buchholz CJ, Chao MV, Placantonakis DG (2014): Selective Lentiviral Gene Delivery to CD133-Expressing Human Glioblastoma Stem Cells.
PLoS One 9: e116114.
Online-Abstract

Ciré S, Da Rocha S, Yao R, Fisson S, Buchholz CJ, Collins MK, Galy A (2014): Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo.
PLoS One 9: e101644.
Online-Abstract

Heidmeier S, Hanauer JR, Friedrich K, Prüfer S, Schneider IC, Buchholz CJ, Cichutek K, Mühlebach MD (2014): A single amino acid substitution in the measles virus F₂ protein reciprocally modulates membrane fusion activity in pathogenic and oncolytic strains.
Virus Res 180: 43-48.
Online-Abstract

Milosch N, Tanriöver G, Kundu A, Rami A, François JC, Baumkötter F, Weyer SW, Samanta A, Jäschke A, Brod F, Buchholz CJ, Kins S, Behl C, Müller UC, Kögel D (2014): Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway.
Cell Death Dis 5: e1391.
Online-Abstract

Abel T, El Filali E, Waern J, Schneider IC, Yuan Q, Muench RC, Hick M, Warnecke G, Madrahimov N, Kontermann RE, Schuettrumpf J, Mueller UC, Seppen J, Ott M, Buchholz CJ (2013): Specific gene delivery to liver sinusoidal and artery endothelial cells.
Blood 122: 2030-2038.
Online-Abstract

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Völker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Mühlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 1-10.
Online-Abstract

Bach P, Abel T, Hoffmann C, Gal Z, Braun G, Voelker I, Ball CR, Johnston ICD, Lauer UM, Herold-Mende C, Muehlebach MD, Glimm H, Buchholz CJ (2013): Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus.
Cancer Res 73: 865-874.
Online-Abstract

Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C (2013): Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.
Gene Ther 20: 16-23.
Online-Abstract

Friedrich K, Hanauer JRH, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanschmann KM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD (2013): DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.
Mol Ther 21: 849-859.
Online-Abstract

Kneissl S, Zhou Q, Schwenkert M, Cosset FL, Verhoeyen E, Buchholz CJ (2013): CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes.
PLoS One 8: e79047.
Online-Abstract

Münch RC, Janicki H, Völker I, Rasbach A, Hallek M, Büning H, Buchholz CJ (2013): Displaying High-affinity Ligands on Adeno-associated Viral Vectors Enables Tumor Cell-specific and Safe Gene Transfer.
Mol Ther 21: 109-118.
Online-Abstract

Rasbach A, Abel T, Münch R, Boller, Schneider-Schaulies J, Buchholz CJ (2013): The receptor attachment function of measles virus hemagglutinin can be replaced with an autonomous protein that binds Her2/neu while maintaining its fusion-helper function.
J Virol 87: 6246-6256.
Text

Völker I, Bach P, Coulibaly C, Plesker R, Abel T, Seifried J, Heidmeier S, Mühlebach MD, Lauer UM, Buchholz CJ (2013): Intrahepatic application of suicide gene-armed measles virotherapeutics: a safety study in transgenic mice and rhesus macaques.
Hum Gene Ther Clin Dev 24: 11-22.
Online-Abstract

Zhou Q, Buchholz CJ (2013): Cell type specific gene delivery by lentiviral vectors.
Oncoimmunology 2: e22566.
Online-Abstract

Buchholz CJ, Sanzenbacher R, Schüle S (2012): The European hospital exemption clause-new option for gene therapy?.
Hum Gene Ther 23: 7-12.
Online-Abstract

Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaulis J, Buchholz CJ (2012): Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.
PLoS One 7: e46667.
Text

Zhou Q, Schneider IC, Edes I, Honegger A, Bach P, Schönfeld K, Schambach A, Wels WS, Kneissl S, Uckert W, Buchholz CJ (2012): T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing.
Blood 120: 4334-4342.
Online-Abstract

Ageichick A, Buchholz CJ, Collins MK (2011): Lentiviral vectors targeted to MHC II are effective in immunization.
Hum Gene Ther 22: 1249-1254.
Online-Abstract

Mühlebach MD, Buchholz CJ, Götz KB (2011): Das Masernvirus im Fokus - von wirksamen und sicheren Impfstoffen über Krebstherapie bis hin zum Gentransfer.
Bulletin zur Arzneimittelsicherheit 2: 20-23.
Text

Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ (2011): DARPins: an efficient targeting domain for lentiviral vectors.
Mol Ther 19: 686-693.
Online-Abstract

Schaser T, Wrede C, Duerner L, Sliva K, Cichutek K, Schnierle B, Buchholz CJ (2011): RNAi-mediated gene silencing in tumour tissue using replication-competent retroviral vectors.
Gene Ther 18: 953-960.
Online-Abstract

Schneider IC, Eckhardt M, Brynza J, Collins MK, Cichutek K, Buchholz CJ (2011): Escape from R-peptide deletion in a γ-retrovirus.
Virology 2: 85-92.
Online-Abstract

Zhou Q, Schneider IC, Gallet M, Kneissl S, Buchholz CJ (2011): Resting lymphocyte transduction with measles virus glycoprotein pseudotyped lentiviral vectors relies on CD46 and SLAM.
Virology 2: 149-152.
Online-Abstract

Anliker B, Abel T, Kneissl S, Hlavaty J, Caputi A, Brynza J, Schneider IC, Muench RC, Petznek H, Kontermann RE, Koehl U, Johnston ICD, Keinänen K, Müller UC, Hohenadl C, Monyer H, Cichutek K, Buchholz CJ (2010): Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors.
Nat Methods 7: 929-935.
Online-Abstract

Anliker B, Longhurst S, Buchholz CJ (2010): Environmental risk assessment for medicinal products containing genetically modified organisms.
Bundesgesundheitsbl – Gesundheitsforsch – Gesundheitsschutz 53: 52-57.
Online-Abstract Text

Mühlebach MD, Schaser T, Zimmermann M, Armeanu S, Hanschmann KMO, Cattaneo R, Bitzer M, Lauer UM, Cichutek K, Buchholz CJ (2010): Liver cancer protease activity profiles support therapeutic options with matrix metalloproteinase-activatable oncolytic measles virus.
Cancer Res 70: 7620-7629.
Online-Abstract

Mühlebach MD, Schüle S, Gerlach N, Schweizer M, Buchholz CJ, Hohenadl C, Cichutek K: Gammaretroviral and Lentiviral Vectors for Gene Delivery.
In: Kurth R, Bannert N (Hrsg.), Retroviruses: Molecular Biology, Genomics and Pathogenesis. Norfolk: Caister Academic Press, 2010. 347-370 ISBN 9781904455554

Buchholz CJ, Mühlebach MD, Cichutek K (2009): Lentiviral vectors with measles virus glycoproteins – dream team for gene transfer?.
Trends Biotechnol 27: 259-265.
Online-Abstract

Funke S, Schneider IC, Glaser S, Mühlebach MD, Moritz T, Cattaneo R, Cichutek K, Buchholz CJ (2009): Pseudotyping lentiviral vectors with the wildtype measles virus glycoproteins improves titer and selectivity.
Gene Ther 16: 700-705.
Online-Abstract

Funke S, Maisner A, Mühlebach MD, Koehl U, Grez M, Cattaneo R, Cichutek K, Buchholz CJ (2008): Targeted cell entry of lentiviral vectors.
Mol Ther 16: 1427-1436.
Online-Abstract

Bach P, Kamphuis E, Odermatt B, Sutter G, Buchholz CJ, Kalinke U (2007): Vesicular stomatitis virus glycoprotein displaying retrovirus-like particles induce a type I IFN receptor-dependent switch to neutralizing IgG antibodies.
J Immunol 178: 5839-5847.
Online-Abstract

Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte M, Wolfer DP, Muller U (2007): The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice.
J Neurosci 27: 7817-7826.
Online-Abstract

Buchholz CJ, Bach P, Nikles D, Kalinke U (2006): Prion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies.
Expert Opin Biol Ther 6: 293-300.
Online-Abstract

Hinz T, Buchholz CJ, van der Stappen T, Cichutek K, Kalinke U (2006): Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
J Immunother 29: 472-476.
Online-Abstract

Kalinke U, Bach P, König M, Buchholz C (2006): Vaccination against prion diseases.
Discov Med 6: 29-34.

Merten CA, Stitz J, Braun G, Medvedovska J, Cichutek K, Buchholz CJ (2006): Fusoselect: cell-cell fusion activity engineered by directed evolution of a retroviral glycoprotein.
Nucleic Acids Res 34: e41.
Online-Abstract

Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R (2006): Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
Cancer Res 66: 7694-7700.
Online-Abstract

Stitz J, Wolfrum N, Buchholz CJ, Cichutek K (2006): Envelope proteins of spleen necrosis virus form infectious human immunodeficiency virus type 1 pseudotype vector particles, but fail to incorporate upon substitution of the cytoplasmic domain with that of Gibbon ape leukemia virus.
J Gen Virol 87: 1577-1581.
Online-Abstract

Finger C, Sun Y, Sanz L, Alvarez-Vallina L, Buchholz CJ, Cichutek K (2005): Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
Cancer Gene Therapy 12: 464-474.
Online-Abstract

Gonin P, Buchholz CJ, Pallardy M, Mezzina M (2005): Gene therapy bio-safety: scientific and regulatory issues.
Gene Ther 12: S146-S152.
Online-Abstract

Hartl I, Schneider RM, Sun Y, Medvedovska J, Chadwick MP, Russel SJ, Cichutek K, Buchholz CJ (2005): Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells.
Gene Ther 12: 918-926.

Merten CA, Stitz J, Braun G, Poeschla EM, Cichutek K, Buchholz CJ (2005): Directed evolution of retrovirus envelope protein cytoplasmic tails guided by functional incorporation into lentivirus particles.
J Virol 79: 834-840.
Online-Abstract

Nikles D, Bach P, Boller K, Merten CA, Montrasio F, Heppner FL, Aguzzi A, Cichutek K, Kalinke U, Buchholz CJ (2005): Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.
J Virol 79: 4033-4042.
Online-Abstract

Sun Y, Finger C, Alvarez-Vallina L, Cichutek K, Buchholz CJ (2005): Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth.
Cancer Gene Ther 12: 900-912.
Online-Abstract

Urban JH, Schneider RM, Compte M, Finger C, Cichutek K, Alvarez-Vallina L, Buchholz CJ (2005): Selection of functional human antibodies from retroviral display libraries.
Nucleic Acids Res 33: e35.

Erlwein O, Buchholz CJ, Schnierle BS (2003): The proline-rich region of the ecotropic Moloney murine leukaemia virus envelope protein tolerates the insertion of the green fluorescent protein and allows the generation of replication-competent virus.
J Gen Virol 84: 369-373.
Online-Abstract

Merten CA, Engelstaedter M, Buchholz CJ, Cichutek K (2003): Displaying epidermal growth factor on spleen necrosis virus-derived targeting vectors.
Virology 305: 106-114.
Online-Abstract

Schneider R, Medvedovska J, Hartl I, Voelker B, Chadwick MP, Russell SJ, Cichutek K, Buchholz CJ (2003): Directed evolution of retroviruses activatable by tumour-associated matrix metalloproteases.
Gene Ther 10: 1370-1380.
Online-Abstract

Bobkova M, Stitz J, Engelstädter M, Cichutek K, Buchholz CJ (2002): Identification of R-peptides in envelope proteins of C-type retroviruses.
J Gen Virol 83: 2241-2246.
Online-Abstract

Vincent S, Tigaud I, Schneider H, Buchholz CJ, Yanagi Y, Gerlier D (2002): Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s).
J Virol 76: 6121-6130.
Online-Abstract

Cichutek K, Schweizer M, Flory E, Buchholz CJ (2001): Regulatorische Aspekte der Anwendung von Gentransfer-Arzneimitteln in der Humanmedizin.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 44: 1083-1089.
Online-Abstract Volltext

Engelstädter M, Buchholz CJ, Bobkova M, Steidl S, Merget-Millitzer H, Willemsen RA, Stitz J, Cichutek K (2001): Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
Gene Ther 8: 1202-1206.

Schweizer M, Flory E, Buchholz CJ, Cichutek K (2001): Retroviral Vectors.
Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 44: 1038-1046.
Online-Abstract Text

Engelstädter M, Bobkova M, Baier M, Stitz J, Holtkamp N, Chu N, Kurth R, Dornburg R, Buchholz CJ, Cichutek K (2000): Targeting human T cells by retroviral vectors displaying antibody fragments selected from a phage display library.
Hum Gene Ther 11: 293-303.
Online-Abstract

Engelstädter M, Bobkova M, Buchholz CJ, Cichutek K (2000): Herstellung retroviraler Zelltargeting-Vektoren.
BIOforum 23: 96-98.

Stitz J, Buchholz CJ, Cichutek K (2000): MLV-derived retroviral pseudotype vectors.
Gene Therapy and Regulation 1: 177-192.
Online-Abstract

Stitz J, Buchholz CJ, Engelstädter M, Uckert W, Blömer U, Schmitt I, Cichutek K (2000): Lentiviral vectors pseudotyped with envelope glycoproteins derived from Gibbon ape leukaemia virus and murine virus 10A1.
Virology 273: 16-20.
Online-Abstract

Stitz J, Steidl S, Merget-Millitzer H, König R, Müller P, Nocken F, Engelstädter M, Bobkova M, Buchholz CJ, Kurth R, Cichutek K (2000): MLV-derived retroviral vectors selective for CD4 expressing cells and are resistant to neutralisation by sera from HIV-infected patients.
Virology 267: 229-236.
Online-Abstract

Buchholz CJ, Stitz J, Cichutek K (1999): Retroviral Cell Targeting Vectors.
Curr Opin Mol Ther 1: 613-621.
Online-Abstract

Firsching R, Buchholz CJ, Schneider U, Cattaneo R, ter Meulen V, Schneider-Schaulies J (1999): Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake.
J Virol 73: 5265-5273.
Online-Abstract

Stitz J, Selbert M, Wehner P, Müller P, König R, Engelstädter M, Bobkova M, Steidl S, Schmitt I, Buchholz C, Kurth R, Cichutek K (1999): Lentiviral vectors derived from apathogenic SIVagm Deutscher AIDS-Kongreß, Essen, 02.–6.06.99.
Eur J Med Res 4: 7.

Buchholz CJ, Peng KW, Morling FJ, Zhang J, Cosset FL, Russell SJ (1998): In vivo selection of protease cleavage sites from retrovirus display libraries.
Nat Biotechnol 16: 951-954.
Online-Abstract